Thus, I-sEV PD-1/CD80 plays an intensive role than IFN-γ in muting antitumour immunity, even simultaneous stimulation of tumour cells with sEV PD-1/CD80 and IFN-γ (both at the pathophysiological concentrations in cancer patients), may still lead to cold tumour phenotype. The gene discussed is CD80; the disease is cancer.